GleamWall
中文EN

KARD Kardigan, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2123613 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.8%
Debt / equity0.00x
Current ratio10.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$0—————
R&D expense$64.36M$56.37M—$49.14M$35.84M—
SG&A expense$22.25M$18.87M—$9.94M$21.29M—
Operating income-$64.81M-$118.76M—-$59.07M-$57.12M—
Pretax income-$58.57M-$116.24M—-$60.16M-$57.45M—
Income tax$0$0—$0$0—
Net income-$58.57M-$116.24M-$56.07M-$60.16M-$57.45M-$18.02M
EBITDA-$64.31M-$118.36M—-$58.87M-$57.02M—
EPS (basic)-0.64-4.61—-4.43-4.64—
EPS (diluted)-0.64-4.61—-4.43-4.64—
Weighted avg. shares (diluted)92.07M25.20M—13.57M12.38M—
Balance sheet
Cash & equivalents$78.89M$384.00M—$169.50M$90.12M—
Short-term investments$392.88M$213.59M————
Current assets$484.46M$610.16M————
PP&E, net$7.30M$7.57M————
Intangibles$26.61M$26.42M————
Total assets$649.25M$721.79M————
Current liabilities$45.62M$70.00M————
Total liabilities$76.73M$106.26M————
Shareholders' equity$572.52M$615.52M-$300.63M-$199.33M-$151.31M-$98.28M
Shares outstanding93.55M93.47M————
Cash flow statement
Operating cash flow-$59.85M——-$46.57M——
Capital expenditure$516,000——$1.36M——
Free cash flow-$60.37M——-$47.93M——
Investing cash flow-$241.87M——-$116.95M——
Financing cash flow-$3.40M——$242.91M——
Depreciation & amortization$500,000$400,000—$200,000$100,000—
Stock-based compensation$16.98M$11.70M—$3.96M$18.65M—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.